Showing 3561-3570 of 20414 results for "".
MS Minute: Chimeric Antigen Receptor T-Cell Therapy for Progressive Multiple Sclerosis: Rationale, Evidence, and Therapeutic Potential
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/chimeric-antigen-receptor-t-cell-therapy-for-progressive-multiple-sclerosis-rationale-evidence-and-therapeutic-potential/56914/CAR T-cell therapy represents a new strategy for treating progressive multiple sclerosis by targeting pathogenic B cells involved in compartmentalized neuroinflammation.Can Early Physical Activity Help Prevent Post Concussive Symptoms in Kids & Teens?
https://reachmd.com/programs/the-jama-report/can-early-physical-activity-help-prevent-post-concussive-symptoms-kids-and-teens/8477/A new study examined whether children who were physically active within seven days of injury have a lower risk of developing post-concussive symptoms.Hair Restoration for Generation X
https://reachmd.com/topics/injectables/hair-restoration-for-generation-x/48725/A Conversation With Suneel Chilukuri, MD, FAAD, FACMSMyths of Preventive Medicine
https://reachmd.com/programs/clinicians-roundtable/myths-of-preventive-medicine/3929/Preventive medicine in primary care has traditionally focused on health promotion and disease prevention. Due to advances in technology, a typical well visit may now include a series of tests to detect early disease. How is this shift toward preventive medicine affecting patient care, survival outcoRewriting the Prognosis: Advances in Endometrial Cancer Diagnosis and Treatment
https://reachmd.com/programs/project-oncology/rewriting-the-prognosis-advances-in-endometrial-cancer-diagnosis-and-treatment/36394/The treatment landscape for endometrial cancer is undergoing a critical transformation as rising incidence, earlier onset, and persistent disparities—especially among younger patients and patients of color—demand urgent attention. Hear from Dr. Kathleen Moore as she unpacks the role of molecular subWomen In Aesthetics: Terri L. Phillips, MD, FAAP, Merz
https://reachmd.com/ma-issues-index/2022-jan-feb/women-in-aesthetics-terri-l-phillips-md-faap-merz/35127/TTR Pathogenic Variant in ATTR-CM: Etiology, Penetrance, and Family Risk
https://reachmd.com/programs/spotlight-attr-cm/attr-cm-ttr-variants-penetrance-family-risk/60806/Differential Diagnosis in ATTR-CM: Excluding AL and Reading the Phenotype
https://reachmd.com/programs/spotlight-attr-cm/al-vs-attr-cm-excluding-al-amyloidosis-and-reading-the-phenotype/60810/Where Should You Spend $100,000 in Your Practice?
https://reachmd.com/topics/practice-development/where-should-you-spend-100000-in-your-practice/35135/Experts weigh in on where you can make the most impactTreatment Decisions in mCSPC: A Review of Retrospective Real-World Evidence
https://reachmd.com/programs/medical-industry-feature/treatment-decisions-mcspc-review-retrospective-real-world-evidence/48990/In metastatic castration-sensitive prostate cancer (mCSPC), combination therapies using androgen receptor pathway inhibitors (ARPIs) and androgen deprivation therapies (ADTs) are now a first-line approach.1 For patients with high-volume and low-volume disease, ERLEADA® (apalutamide) plus ADT is clas